Portal Instruments’ CEO Patrick Anquetil was recently interviewed by Medgadget about Portal’s innovative needle-free drug delivery technology and the impact that that could have on existing treatment options of multiple chronic conditions.

To view the article on the Medgadget website, click here.

 

About Portal Instruments

Portal Instruments is a Series B funded medical device company focused on advanced drug delivery and backed by strategic and venture investors. Portal Instruments is developing and commercializing a highly innovative needle-free drug delivery platform technology to transform the administration of medicines and improve the patient experience for chronic diseases. Portal’s needle-free delivery technology is derived from research at MIT and enables the administration of high viscosity biologic drugs with less discomfort and without the anxiety of handling needles. Real time tracking and reporting sets a new standard for interactivity between the patient and care teams, monitoring adherence and potentially improving patient outcomes. Portal Instruments’ Quality Management System is ISO 13485 certified. For more information, please visit www.portalinstruments.com or follow @portalcambridge on Twitter.

 

About Medgadget

Medgadget reports on medical technology from around the world. The company covers the latest medical devices and approvals, technology breakthroughs and discoveries, conduct exclusive interviews with med tech leaders, and file reports from healthcare conferences. Medgadget was founded in 2004 and is known for its up-to-date coverage of the international medical technology news, health care trends, and medical research. For more information, go to medgadget.com.

Pages of the Portal Instruments website may contain links to third party websites that are not under the control of Portal Instruments. Portal Instruments is not responsible for the content of any such site and the inclusion of these links does not imply the endorsement of the content of the linked site by Portal Instruments.